21642-98-8

Basic information

• Product Name: 4-Methoxy-2-oxo-1,2-dihydro-pyridine-3-carbonitrile
• Synonyms: 3-Cyano-4-methoxy-2-pyridone;MPCN 4-Methoxy-2-oxo-1,2-dihydro-pyridine-3-carbonitrile;3-Cyano-4-methoxy-2-pyridone≥ 98%(HPLC);4-METHOXY-2-OXO-1,2-DIHYDRO-3-PYRIDINECARBONITRILE;4-Methoxy-2-oxo-1,2-dihydro-pyridine-3-carbonitrile;3-CYANO-2-HYDROXY-4-METHOXYPYRIDINE;3-Cyano-4-methoxyl-2-(1H)-pyridione;3-CYANO-4-METHOXY-2-(1H)-PYRIDINONE
• CAS NO: 21642-98-8
• Molecular Formula: C₇H₆N₂O₂
• Molecular Weight: 150.13
• EINECS: 1312995-182-4
• Product Categories: blocks;Pyridines;API intermediates;Pyridine;Heterocycle-Pyridine series;Aromatics, Heterocycles, Metabolites & Impurities, Neurochemicals, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 21642-98-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 293°C
• Boiling Point: 421.8 °C at 760 mmHg
• Flash Point: 208.9 °C
• Appearance: Pale yellow/Crystalline Solid
• Density: 1.27 g/cm³
• Vapor Pressure: 2.54E-07mmHg at 25°C
• Refractive Index: 1.547
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Soluble in Dimethyl sulfoxide.
• PKA: 7.99±0.10(Predicted)
• Sensitive: Hygroscopic
• CAS DataBase Reference: 4-Methoxy-2-oxo-1,2-dihydro-pyridine-3-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methoxy-2-oxo-1,2-dihydro-pyridine-3-carbonitrile(21642-98-8)
• EPA Substance Registry System: 4-Methoxy-2-oxo-1,2-dihydro-pyridine-3-carbonitrile(21642-98-8)

Safety Data

• Hazard Codes: Xi,Xn,T
• Statements: 20/21/22-36/37/38-22-25
• Safety Statements: 26-36/37/39-45-24/25
• RIDADR: 3439
• HazardClass: IRRITANT
• PackingGroup: III
• Hazardous Substances Data: 21642-98-8(Hazardous Substances Data)

Usage

Chemical Properties

Off-white crystalline powder

Uses

Different sources of media describe the Uses of 21642-98-8 differently. You can refer to the following data:
1. N-Demethylricinine is a demethylated metabolite of Ricinine (R495550), an alkaloid extract from the castor-oil plant (Ricinus communalis). N-Demethylricinine is an impurity in the production of Gime racil.
2. Used as a intermediate for gimeracil and pharmaceutical application.

InChI:InChI=1/C7H6N2O2/c1-11-6-2-3-9-7(10)5(6)4-8/h2-3H,1H3,(H,9,10)

Upstream product

• 5515-16-2 2-(methoxyethylidene)propanedinitrile 
• 95689-38-6 1,1-dicyano-4-(N,N-dimethylamino)-2-methoxy-1,3-butadiene 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 5417-82-3 (1-ethoxyethylidene)malononitrile 
• 98645-42-2 2-bromo-4-methoxypyridine-3-carbonitrile 
• 98651-70-8 2-amino-4-methoxypyridine-3-carbonitrile 

Downstream Products

• 950201-66-8 C₂₃H₂₉N₃O₃ 
• 950201-65-7 C₂₃H₂₉N₃O₄ 
• 950201-67-9 C₃₀H₃₄FN₃O₃ 
• 520-78-5 4-hydroxy-1-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile 

Relevant articles and documents

DIVALENT NUCLEOBASE COMPOUNDS AND USES THEREFOR

Described herein are novel divalent nucleobases that each bind two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone (a genetic recognition reagent, or genetic recognition reagent). In one embodiment, the genetic recognition reagent is a peptide nucleic acid (PNA) or gamma PNA (?PNA) oligomer. Uses of the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.

Tricyclic thienopyridine-pyrimidones/thienopyrimidine-pyrimidones as orally efficacious mGluR1 antagonists for neuropathic pain

Introduction of small unsaturated alkylamino groups at the 4-position of the A-ring of the tricyclic framework (triazafluorenone) afforded extremely potent and selective mGluR1 antagonists with desirable properties. Compounds 11q and 11s are active in the

SUBSTITUTED PYRIDINONES

Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.